Literature DB >> 16376869

Nitric oxide is a preconditioning mimetic and cardioprotectant and is the basis of many available infarct-sparing strategies.

Michael V Cohen1, Xi-Ming Yang, James M Downey.   

Abstract

Ischemic preconditioning is a powerful infarct-sparing intervention. Intensive investigations have revealed many of the signaling steps used to elicit this protection. One of the steps involves activation of nitric oxide synthase (NOS) by phosphorylation, with the production of NO and subsequent activation of guanylyl cyclase, production of cGMP, activation of protein kinase G, opening of mitochondrial KATP channels, and generation of reactive oxygen species. The latter act as second messengers to activate critical kinase cascades that trigger entrance into the preconditioned state. Thus, NO exposure before ischemia can act as a powerful preconditioning mimetic. Elevating NO just prior to or at reperfusion can still be an effective cardioprotective strategy. Activation of NOS or production of NO can be done pharmacologically with exogenous agents to trigger this cascade. Many of these strategies are already available and safe.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16376869     DOI: 10.1016/j.cardiores.2005.10.021

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  52 in total

1.  Fibroblast growth factor-2-induced cardioprotection against myocardial infarction occurs via the interplay between nitric oxide, protein kinase signaling, and ATP-sensitive potassium channels.

Authors:  Janet R Manning; Gregory Carpenter; Darius R Porter; Stacey L House; Daniel A Pietras; Thomas Doetschman; Jo el J Schultz
Journal:  Growth Factors       Date:  2012-02-06       Impact factor: 2.511

Review 2.  Role of glycogen synthase kinase-3beta in cardioprotection.

Authors:  Magdalena Juhaszova; Dmitry B Zorov; Yael Yaniv; H Bradley Nuss; Su Wang; Steven J Sollott
Journal:  Circ Res       Date:  2009-06-05       Impact factor: 17.367

3.  Hyperlipidaemia induced by a high-cholesterol diet leads to the deterioration of guanosine-3',5'-cyclic monophosphate/protein kinase G-dependent cardioprotection in rats.

Authors:  Z Giricz; A Görbe; J Pipis; D S Burley; P Ferdinandy; G F Baxter
Journal:  Br J Pharmacol       Date:  2009-10-20       Impact factor: 8.739

4.  Transfused older stored red blood cells improve the clinical course and outcome in a canine lethal hemorrhage and reperfusion model.

Authors:  Steven B Solomon; Irene Cortés-Puch; Junfeng Sun; Kenneth E Remy; Dong Wang; Jing Feng; Sameena S Khan; Derek Sinchar; Daniel B Kim-Shapiro; Harvey G Klein; Charles Natanson
Journal:  Transfusion       Date:  2015-07-15       Impact factor: 3.157

5.  Disruption of caveolae blocks ischemic preconditioning-mediated S-nitrosylation of mitochondrial proteins.

Authors:  Junhui Sun; Mark J Kohr; Tiffany Nguyen; Angel M Aponte; Patricia S Connelly; Shervin G Esfahani; Marjan Gucek; Mathew P Daniels; Charles Steenbergen; Elizabeth Murphy
Journal:  Antioxid Redox Signal       Date:  2011-08-11       Impact factor: 8.401

6.  H(2)S and HS(-) donor NaHS releases nitric oxide from nitrosothiols, metal nitrosyl complex, brain homogenate and murine L1210 leukaemia cells.

Authors:  Karol Ondrias; Andrej Stasko; Sona Cacanyiova; Zdena Sulova; Olga Krizanova; Frantisek Kristek; Lubica Malekova; Vladimir Knezl; Albert Breier
Journal:  Pflugers Arch       Date:  2008-05-06       Impact factor: 3.657

7.  Activation of beta-adrenoceptors mimics preconditioning of rat-isolated atria and ventricles against ischaemic contractile dysfunction.

Authors:  Peter E Penson; William R Ford; Emma J Kidd; Kenneth J Broadley
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-07-29       Impact factor: 3.000

8.  Arginase inhibition improves coronary microvascular function and reduces infarct size following ischaemia-reperfusion in a rat model.

Authors:  J Grönros; A Kiss; M Palmér; C Jung; D Berkowitz; J Pernow
Journal:  Acta Physiol (Oxf)       Date:  2013-04-15       Impact factor: 6.311

Review 9.  Mitochondria as a drug target in ischemic heart disease and cardiomyopathy.

Authors:  Andrew M Walters; George A Porter; Paul S Brookes
Journal:  Circ Res       Date:  2012-10-12       Impact factor: 17.367

10.  Mitochondrial nitroalkene formation and mild uncoupling in ischaemic preconditioning: implications for cardioprotection.

Authors:  Sergiy M Nadtochiy; Paul R S Baker; Bruce A Freeman; Paul S Brookes
Journal:  Cardiovasc Res       Date:  2008-12-02       Impact factor: 10.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.